{"id":"W1998198982","doi":"10.1016/j.ygyno.2006.10.006","title":"Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel—ANZGOG 02-01","year":2006,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Health Canada; Pfizer Canada; Pfizer","keywords":"Medicine; Docetaxel; Paclitaxel; Neutropenia; Internal medicine; Chemotherapy; Ovarian cancer; Oncology; Toxicity; Cancer; Surgery","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001038729,0.001725579,0.002555951,0.0006034479,0.0005314464,0.001500458,0.001372757,0.001668767,0.008148665],"category_scores_gemma":[0.0008605717,0.0008048835,0.00153066,0.0005222753,0.001463743,0.001043504,0.0004987112,0.005296081,0.002077654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001278838,"about_ca_system_score_gemma":0.001958593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003146414,"about_ca_topic_score_gemma":0.009847968,"domain_scores_codex":[0.9996971,0.0001194582,0.00001160314,0.0000632346,0.0000195584,0.00008911276],"domain_scores_gemma":[0.9993172,0.00009158091,0.00009909362,0.00005760813,0.000023265,0.0004112757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.77812,0.05921357,0.004274587,0.0008199415,0.001670194,0.0002868543,0.0003726296,0.004498411,0.01796159,0.0007731922,0.01362678,0.1183822],"study_design_scores_gemma":[0.8036044,0.1849476,0.005389739,0.00002870673,0.0003200981,0.0001691207,0.00007407853,0.0009956901,0.001054714,0.0002060828,0.003183174,0.0000267109],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985943,0.002349662,0.0004941995,0.002044237,0.0005168533,0.00234761,0.00202998,0.0002756327,0.003998983],"genre_scores_gemma":[0.9744647,0.002573995,0.001385304,0.002338434,0.0003636302,0.002558535,0.003982921,0.00008230085,0.01225022],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008148665,"threshold_uncertainty_score":0.02726001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02246963538514211,"score_gpt":0.3245821224454167,"score_spread":0.3021124870602745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}